Jio Platforms achieved an 11.4% increase in operating revenue to Rs 40,475 crore alongside an EBITDA expansion of 17%, driven by a 250 basis points margin improvement. Customer growth remained robust, with 9.1 million net additions pushing the total user base to 542.4 million as churn dropped to 1.6%. Higher engagement was evident as monthly consumption reached 44.2 GB per user, lifting total network data traffic by 22.1% to 71.3 billion GB.
Key points
The corporate milestone represents Jio Platforms' first financial scorecard since complet…: The corporate milestone represents Jio Platforms' first financial scorecard since completing its public market listing on October 28.
Consistent subscriber additions and rising user consumption contributed to a 250 basis po…: Consistent subscriber additions and rising user consumption contributed to a 250 basis points enhancement in operating margins.
Reliance group reclaimed the title of India's most valuable business conglomerate over th…: Reliance group reclaimed the title of India's most valuable business conglomerate over the Tata group following Jio's public debut.
Sources checked by our analysis pipeline: 1
Jio O2 results: Jio Platforms reported a 13.7% year-on-year increase in consolidated net profit to Rs 8,389 crore for the September quarter of FY27, while revenue from operations rose 11.4% to Rs 40,475 crore. The company also recorded growth across key operational parameters, with its customer base expanding to 542.4 million, data traffic increasing 22.1% and average revenue per user (ARPU) rising to Rs 218.8.
The results, announced on Friday, mark the company's first earnings announcement since its stock market debut on October 28.
Jio Platforms' consolidated net profit increased to Rs 8,389 crore in Q2 FY27 from Rs 7,379 crore in the corresponding quarter last year. Revenue from operations climbed to Rs 40,475 crore from Rs 36,332 crore over the same period.
The company also reported an improvement on a sequential basis, with net profit rising 8% from Rs 7,765 crore in the June quarter. Revenue increased 3% quarter-on-quarter.
Earnings before interest, taxes, depreciation and amortisation (EBITDA) grew 17% year-on-year during the quarter, driven by revenue growth, operating leverage and a 250 basis points expansion in margins.
Biopharmaceutical firm Vir Biotechnology has named David Liu as its new chief medical officer to oversee clinical leadership. Liu steps into the position after previously holding the identical executive role at Nuvation Bio. The appointment was highlighted within an ongoing industry tracking series that monitors key executive transitions.
Margin compression during the quarter stemmed from heavy digital commerce investments, absorbed cost inflation, and rising finance expenses tied to increased borrowings. A calendar shift pushing key festive events into the subsequent period, combined with higher depreciation from ongoing physical expansion, further weighed on the bottom line. Despite these near-term headwinds, operational volume remained steady as footfalls and engagement translated into positive top-line growth.
The top executive clarified that the energy giant is not evaluating a split of its operations, moving swiftly to shut down recent market rumors. By firmly addressing the matter, leadership aims to reassure stakeholders and maintain focus on the firm's integrated corporate structure. The direct dismissal leaves no ambiguity regarding the firm's immediate organizational strategy.